anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
MEDICAL SCHEME MEMBER : Prior Med e Card - When Member attends Health Service Provider including Doctor, use special Short Code Number designated to send in Mobile Message of the Practice Number, Via Prior's Systems & utilizing Cellular Gateway, or WASP etc transfer message to Scheme Administration system, using Members Cell Number - to identify Unique Membership & other significant information, including Premium payments, outstanding Benefits etc - Do auto Validation of Member & other required criteria - and send Validation Message back to Health Service Provider - Cell Phone. All Automatic - all in virtual real time. NON MEDICAL SCHEME MEMBER Prior Med e Health - Mobile Health Voucher where Person acquires a Voucher via various methods, cash from outlet, via Employer, on Credit /Debit Card etc. All purchases directed to Prior Systems - who then issue Virtual Health Voucher Code Number to the Purchasers Cell Phone. This Purchaser can then attend a Health Service Provider in Prior's special designated Network, to redeem the Voucher & obtain Treatment etc to value of the Voucher. There are many other adaptable Products, all listed in the enclosed Prior Investment Schedule.
The rationale of this study is to compare repeatability, reproducibility and agreement of both, AS-OCT(s) and Pentacam. In our department three different AS-OCT devices and a HR Scheimpflug imaging device are currently in use for clinical routine to measure the cornea. Among refractive and anterior segment surgeons, there is no preferred and accepted method for accurate measurements of the corneal curvature. The four diagnostic tools are based on different technical and physical imaging principles and to date only limited information on their comparability exist. One advantage of ASOCT represents faster imaging speed when compared to Scheimpflug imaging. Thus, imaging misalignment, segmentation errors and defocus aberration can most likely be avoided by AS-OCT. Chen et al demonstrated that HR Scheimpflug imaging measurements of CCT were systematically higher than the measurements provided by FD AS-OCT. Further, repeatability, reproducibility and agreement of AS-OCT and Scheimpflug imaging device will be assessed during follow-up.
Posttraumatic headaches are one of the most common and controversial secondary headache types. After a mild traumatic brain, an estimated 11% to 82% of people develop a postconcussion syndrome, which has been controversial for more than 160 years. Headache is estimated as present in 30% to 90% of patients after a mild head injury. Most headaches are tension-type-like or migraine-like. Headaches in civilians, soldiers, athletes, and postcraniotomy are reviewed. The treatments are the same as for the primary headaches. Persistent posttraumatic headaches can continue for many years.
Nicardipine hydrochloride capsules for oral administration each contain 20 mg or 30 mg of nicardipine hydrochloride. Nicardipine hydrochloride capsules are a calcium ion influx inhibitor (slow channel blocker or calcium channel blocker).

Nicardipine hydrochloride is a dihydropyridine structure with the IUPAC (International Union of Pure and Applied Chemistry) chemical name 2-(benzyl-methyl amino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate monohydrochloride, and it has the following structure:

Nicardipine hydrochloride is a greenish-yellow, odorless, crystalline powder that melts at about 169°C. It is freely soluble in chloroform, methanol and glacial acetic acid, sparingly soluble in anhydrous ethanol, slightly soluble in n-butanol, water, 0.01 M potassium dihydrogen phosphate, acetone and dioxane, very slightly soluble in ethyl acetate, and practically insoluble in benzene, ether and hexane. It has a molecular weight of 515.99.

Each capsule, for oral administration, contains 20 mg or 30 mg of nicardipine hydrochloride. In addition, each capsule contains the following inactive ingredients: magnesium stearate, pregelatinized starch, titanium dioxide, gelatin and FD&C Blue #1. The colorants used in the capsules are black iron oxide, FD&C Blue #2, FD&C Red #40, D&C Yellow #10 and FD&C Blue #1. In addition, the 30 mg capsules also contain propylene glycol.
This research was conducted to determine the intensity of acupressure treatment for gastrointestinal problems, pain and anxiety after bariatric surgery. The research was conducted using a placebo group, randomized controlled, detailed research model. The data of the study was collected at Aktif Private Kocaeli Hospital General Surgery Clinic between January 2022 and February 2023. The study was conducted with 90 (30 control, 30 intervention and 30 placebo) patients who underwent bariatric surgery. The data were brought together with the patient identification formula, postoperative gastrointestinal functions information formula, abdominal distension formula, visual analog scale, state-trait anxiety inventory scale, visual comparison operation, and patient happiness formula. The data were analyzed with the SPSS for Windows 22 package program. Records of numbers, percentages, minimum and maximum values, averages and standard deviations in the analysis of data. Mann Whitney U analysis, LSD, Dunnet C, Kruskall Wallis, Will coxon analyzes and t test records. The results were interpreted at the p\< 0.05 significance level. Gastrointestinal capacity and recovery time, stool and gas output rates, difference in distension and abdominal pain score amounts, oral intake amounts and retching difference of the patients in acupressure, control and placebo distribution at the 6th, 12th, 24th and 48th months of the surgery were investigated. Children's movements and vomiting were evaluated with visual comparison performance. Anxiety was measured with the State-Trait Anxiety Inventory Scale at the ages of 6, 12, 24 and 48 after treatment. He recorded the Patient Satisfaction Form to obtain the patients' satisfaction after acupressure.
As with all antipsychotic agents, haloperidol has been associated with persistent dyskinesias. Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome is characterized by rhythmical involuntary movements of tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities and the trunk.

There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, this syndrome may be masked. 

It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and if the medication is stopped at that time, the full syndrome may not develop.
Hypoxic-ischemic brain damage (HIBD) is a leading cause of neonatal death and neurological dysfunction for which no particularly effective treatment is available. Stem cells possess multi-directional differentiation potential and can secrete a variety of cytokines. They not only have the ability to replace tissue and repair lesions but also improve neurological damage caused by HIBD through paracrine mechanisms, including anti-apoptosis, reduction of inflammation, and promotion of endogenous repair. Recently, as research on stem cells, particularly mesenchymal stem cells, has deepened, the application of stem cells in treating HIBD has become a prominent research topic, yielding fruitful results, particularly regarding the neuroprotective effects and mechanisms of the stem cell paracrine pathway. With advances in stem cell injection, distribution, and biomaterial incorporation, applications of stem cells have become more widespread and comprehensive. This review summarizes and discusses the research progress on stem cells in HIBD treatment to provide theoretical support for HIBD treatment and enhance the feasibility of clinical translation.
The present invention relates to a composite preparation of aconite and sulfur for treatment of drug addiction and alcoholism and alleviation of withdrawal symptoms thereof. According to the present invention, the composite preparation of aconite and sulfur is prepared by the steps of: mixing potato juice and soybean juice in the weight ratio of 1:1 as the effective ingredients; decompounding starch by adding a-amylase; inoculating Aspergillus oryzae var. oryzae mold growth to the juice; fermenting the juice at temperatures of 40 to 50C for 48 to 92 hours; adding sulfur crystals designated as the pharmacopeia, raising the fermentation temperature to 55 to 70C, and further fermenting the juice for 48 to 92 hours; and filtering and drying the juice. The composite preparation of aconite and sulfur prepared by the above steps contains 75-80% by weight of the sulfur crystals, 5-7% by weight of mica, 0.8-1.2% by weight of alum, 0.7-0.9% by weight of nontoxic processed aconite, and 10-13% by weight of starch as a binder. According to the present invention, the composite preparation of aconite and sulfur contains a small amount of the processed aconite with slight toxicity and fermented sulfur crystals, heated mica, and alum. Accordingly, the composition containing the aconite and the sulfur of the present invention has the effects of relieving the pains by calming the central nerves related to the withdrawal symptoms of various kinds of drug addictions and alcoholism through its effective ingredients and treating the withdrawal symptoms for a short time as compared with the other existing anti-addiction agents. Further, the composition containing the aconite and the sulfur of the present invention does not cause a secondary addiction, a recurrence of the addiction after the treatment, or a physical side effect unlike the existing anti-addiction agents and provides better treatment effect for various kinds of addictions.
Microscopic colitis, a diagnosis under the umbrella term of inflammatory bowel disease, is a prevalent cause of watery diarrhea, often with symptoms of urgency and bloating, typically observed in older adults aged ≥ 60 years. Its incidence has been reported to exceed those of ulcerative colitis and Crohn's disease in some geographical areas. Although nonpathognomonic endoscopic abnormalities, including changes of the vascular mucosal pattern; mucosal erythema; edema; nodularity; or mucosal defects, e.g., "cat scratches" have been reported, a colonoscopy is typically macroscopically normal. As reliable biomarkers are unavailable, colonoscopy using random biopsies from various parts of the colon is compulsory. Based on the histological examination under a microscope, the disease is divided into collagenous (with a thickened subepithelial collagenous band) and lymphocytic (with intraepithelial lymphocytosis) colitis, although incomplete forms exist. In routine clinical settings, the disease has a high risk of being misdiagnosed as irritable bowel syndrome or even overlooked. Therefore, healthcare providers should be familiar with clinical features and rational management strategies. A 6-8-week oral budesonide treatment course (9 mg/day) is considered the first-line therapy, but patients often experience relapse when discontinued, or might become intolerant, dependent, or even fail to respond. Consequently, other therapeutic options (e.g., bismuth subsalicylate, biologics, loperamide, bile acid sequestrants, and thiopurines) recommended by available guidelines may be prescribed. Herein, clinically meaningful data is provided based on the latest evidence that may aid in reaching a diagnosis and establishing rational therapy in geriatric care to control symptoms and enhance the quality of life for those affected.
Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
OBJECTIVES: Desmodium triquetrum DC (Fabaceae) is a plant commonly used in Indian traditional medicine to treat allergies. Asthma is a severe condition, with an estimated 300 million deaths annually, which could increase to 400 million by 2025. Flavonoids, a class of compounds found in many plants, have been found to have beneficial effects in treating asthma. In this study, researchers focused on three flavonoids, Baicalein, Naringin, and Neohesperidin, derived from Desmodium triquetrum DC, to investigate their potential as a treatment for asthma.
METHODS: The study used an aerosolized ovalbumin-induced asthma model to evaluate the effects of the flavonoids on various substances in bronchoalveolar lavage fluid, including total differential leukocyte, nitrite, nitrate, TNF, IL-4, and IL-13. The researchers also measured the levels of myeloperoxidase and malondialdehyde in the lungs.
RESULTS: The results showed that ovalbumin-induced airway hyper-responsiveness led to a significant increase in pro-inflammatory cytokine levels. However, the flavonoids significantly decreased the severity of airway inflammation. Histopathology results also supported the effectiveness of the flavonoids. These findings suggest that these flavonoids could be a supplementary and alternative treatment for asthma by inhibiting the pro-inflammatory pathway.
CONCLUSIONS: The findings suggest that the isolated compounds have the potential to act cumulatively to decrease the levels of the tested cytokines, normalize eosinophil and activated lymphocyte counts, and significantly reduce MPO and MDA. This indicates a possible respiratory mechanism of action for the drugs.
The chronic nature of Inflammatory Bowel Disease (IBD) leads to a significant impact on patients' lives, beyond intestinal symptoms alone. The sequelae of this can be seen in the increased rates of depression and reduced quality of life (QoL). Surgery may provide a way to effectively induce long-term symptoms remission, although there is a short postoperative transitory period whereas quality of life might decrease. Over the last years, increasing interest has been gained by perioperative recovery protocols, aiming to accelerate functional recovery and to reduce complications. Some of these protocols include an in-depth discussion with both dedicated nurses and/or surgeons to decrease surgery-associated stress reaction. Nevertheless, no one of the proposed protocols has included a psychological assessment in order to correlate it with functional recovery. We suggest that studying the psychological characteristics of the patients (with a specific focus on mindfulness) could lead to open a new research front to optimize patients' outcomes.
PURPOSE:To provide a liquid medicine for the treatment of athlete's foot, exhibiting excellent drug action on moist athlete's foot as well as dry athlete's foot, capable of completely curing the athlete's foot in a short time and producible in a mass at a low cost. CONSTITUTION:The objective liquid medicine for the treatment of athlete's foot is produced by immersing 3-200 pts.wt. (preferably 10-100 pts.wt.) of the bulb, sliced bulb or ground bulb of a plant of the family Amaryllidaceae (e.g. plant of the genus Lycoris) in 100 pts.wt. of an aqueous solution containing a carboxylic acid as a main component and preferably mixing the immersion product with several % of menthol.
Trabeculectomy is widely used as a surgical treatment of uncontrolled open glaucoma. Success of trabeculectomy at halting or slowing glaucoma progression primarily relies on the extent of conjunctival and sclera wound healing. The success rates of trabeculectomy increased dramatically with the introduction of anti-metabolites. For more than two decades mitomycin-c (MMC), a chemotherapeutic agent capable of decreasing fibroblast activity and modulating wound healing at the bleb, has been used with trabeculectomy. The complications of MMC are well known and several studies have described various methods of application based on exposure time, dose and surface area. Numerous retrospective and prospective studies have compared the efficacy of MMC applied beneath the conjunctival flap with soaked sponges versus intrascleral application. In 2008, Lee et al. first described an alternative route of application: subconjunctival injection of MMC directly into the intra-Tenon area. Seventy-six eyes with primary and secondary open angle glaucoma underwent trabeculectomy with this approach and were followed for one year post-operatively. Eighty-six percent of eyes achieved an IOP \<21 mm Hg and 57% an IOP\<14 mm Hg at one year without adjunctive drops. Transient complications included hyphema, bleb leak and choroidal detachment. The advantages of injected MMC are primarily in controlling the exact dosage and area of application and reduced surgical time. Lim et al. retrospectively reviewed the outcomes of trabeculectomy in 57 eyes using sponge application directly to the sclera versus intra-tenon injection. IOP was significantly lower in the injection group at 1 month, 1, 2, and 3 years. Trabeculectomy success (IOP\<21mm Hg or IOP \>20% below baseline without medications or additional surgery) was greater in the injection group at 3 years. The sponge group experienced more encapsulated blebs but complication rates were similar in both groups. To date, there have been no prospective studies comparing the IOP-lowering efficacy and safety of intra-tenon injection versus direct scleral application of MMC.
Patients undergo radiotherapy and receive vorinostat PO QD on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients also receive temozolomide PO QD on days 1-42. Beginning 4-6 weeks later, patients receive vorinostat PO QD on days 1-7 and 15-21 and temozolomide PO QD on days 1-5. Treatment with vorinostat and temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
This is a multi center, double-blind, randomized, placebo-controlled trial. A total of 80 patients will be randomized according to a 1: 1 randomization schedule. To participate in the trial, patients must have a current Diabetic Foot Ulcer (DFU) for between 60 days to 2 years at the screening visit. In the 2-week period between screening and baseline visit, the patient's DFU must not have healed by 30% or more, in wound area, while being treated with SWT twice a week during this screening period.

During the treatment period of 4 weeks all patients will be examined on a weekly basis by the site staff. Treatment with SWT plus the study gel (IZN-6D4 Gel or placebo gel) (including any necessary debridement) will be administered at these weekly visits. In addition, the patient or caregiver will be trained to perform SWT plus the study treatment at home once midweek between visits.
Self-reported weight and height serve as important metrics in estimating overweight and obesity prevalence within epidemiological studies, primarily due to their cost and time efficiency. However, the accuracy and reliability of these self-reported measures remain controversial, with conflicting reports emerging from different regions. This study aims to compare self-reported weight and height with measured values among young female adults in the United Arab Emirates. A cross-sectional study of 131 female university students aged 17-27 reported their weight and height on a self-administered questionnaire and on the same day had their height and weight measured. Body Mass Index (BMI) values of both self-reported and measured weight and height were calculated and categorized according to the World Health Organization's cut-off points. Overall, 87% of students had a resultant self-reported BMI value within their actual BMI category. The mean differences between self-reported and measured weight and height in the present study were -0.92 kg and 0.38 cm, respectively. Results indicated strong agreement between self-reported and direct measurements, as demonstrated by weighted Kappa statistics (kappa = 0.87). Bland & Altman plots illustrated that the majority of values fell within the limits of agreement (2 SD), with no systemic bias detected. BMI calculated from self-reported data demonstrates high sensitivity and specificity. Linear regression analyses revealed that self-reported weight (r2 = 0.973; p<0.001), height (r2 = 0.902; p<0.001), and BMI (r2 = 0.964; p<0.001) accurately predicted measured weight, height, and BMI. The study's results highlight the ability of female university students in the UAE to accurately provide self-reports of their weight and height. This finding provides further support for the utilization of self-reported data on height and weight as a valid method for collecting anthropometric information.
PURPOSE: A therapeutic agent usign a recombinant vector cotnaining a gene encoding adenylate cyclase activating polypeptide 1(pituitary) is provided to suppress proliferation of cervical cancer cells. CONSTITUTION: A recombinant vector for suppressing cervical cancer cell proliferation contains a gene encoding adenylate cyclase activating polypeptide 1(pituitary) or fragment thereof. The gene encoding ADCYAP1 is a cDNA of sequence number 1 derived from human body. A pharmaceutical composition for treating cervical cancer contains the recombinant vector as an active ingredient, having the gene encoding ADCYAP1 or fragment thereof. The pharmaceutical composition for treating cervical cancer contains ADCYAP1 protein or fragment thereof. ADCYAP1 protein has a base sequence of sequence number 2.
The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
Up to 12 facilities will be assigned one of three intervention groups (4 facilities per group). The strategies have no yet been identified but will be through other activities in the PrEPARE study.
The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.